Breaking Finance News

Achillion Pharma (NASDAQ:ACHN) target price raised to $13.00, issued a report today by Wedbush

Stating as potential upside of 0.54%, Wedbush bumped up the target of Achillion Pharma (NASDAQ:ACHN) to $13.00

On 9/22/2016, Wedbush released a statement about Achillion Pharma (NASDAQ:ACHN) upped the target price from $0.00 to $13.00 that suggested an upside of 0.54%.

Having a price of $8.44, Achillion Pharma (NASDAQ:ACHN) traded 2.96% higher on the day. With the last stock price close up 3.37% from the 200-day moving average, compared to the S&P 500 which has decreased -0.01% over the same time period. ACHN has recorded a 50-day moving average of $8.48 and a two hundred day average of $8.41. Volume of trade was up over the average, with 4,856,974 shares of ACHN changing hands over the typical 1,438,300

Performance Chart

Achillion Pharma (NASDAQ:ACHN)

With a total market value of $0, Achillion Pharma has PE ratio of 177.35 with a one year low of $5.57 and a one year high of $10.95 .

A total of 5 analysts have released a report on Achillion Pharma. Two analysts rating the company a strong buy, one analyst rating the company a buy, three analysts rating the company a hold, one analyst rating the company a underperform, and finally zero analysts rating the company a sell with a 12-month price target of $9.40.

General Company Details For Achillion Pharma (NASDAQ:ACHN)

Achillion Pharmaceuticals, Inc. is a biopharmaceutical company. The Company's primary business is to discover, develop and commercialize small molecule therapeutics for the treatment of infectious diseases and immune system disorders. The Company is focused on its complement inhibitor platform, directed at advancing small molecule compounds that have the potential to be used in the treatment of immune-related diseases associated with the complement system. The complement system is part of the body's immune system. The Company has initiated a first-in-human Phase I clinical trial for its first complement factor D inhibitor, ACH-4471, to assess safety, tolerability, pharmacokinetics, or PK, and pharmacodynamics, or PD. The Company has developed a portfolio of drug candidates, including odalasvir, ACH-3422 and sovaprevir.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *